Literature DB >> 18952586

Aggressive infantile embryonal tumors.

Tobey J MacDonald1.   

Abstract

Embryonal tumors are the most common brain tumors in infants less than 36 months. Histologically characterized as undifferentiated small, round cell tumors with divergent patterns of differentiation, these include medulloblastoma, the most common form of embryonal tumor, as well as supratentorial primitive neuroectodermal tumor, medulloepithelioma, ependymoblastoma, medullomyoblastoma, melanotic medulloblastoma, and atypical teratoid/rhabdoid tumor. All are similarly aggressive and have a tendency to disseminate throughout the central nervous system. Because of efforts to avoid craniospinal irradiation in an attempt to lessen treatment-related neurotoxicity, management of these tumors in infants is unique. Outcomes remain similarly poor among all the tumor types and, therefore, identification of specific molecular targets that have prognostic and therapeutic implications is crucial. The molecular and clinical aspects of the 3 most common aggressive infantile embryonal tumors, medulloblastoma, supratentorial primitive neuroectodermal tumor, and atypical teratoid/rhabdoid tumor, are the focus of this review.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18952586      PMCID: PMC3674573          DOI: 10.1177/0883073808321769

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  70 in total

1.  Diffusion-weighted imaging and fluid attenuated inversion recovery imaging in the evaluation of primitive neuroectodermal tumors.

Authors:  E Erdem; R A Zimmerman; J C Haselgrove; L T Bilaniuk; J V Hunter
Journal:  Neuroradiology       Date:  2001-11       Impact factor: 2.804

2.  Prediction of central nervous system embryonal tumour outcome based on gene expression.

Authors:  Scott L Pomeroy; Pablo Tamayo; Michelle Gaasenbeek; Lisa M Sturla; Michael Angelo; Margaret E McLaughlin; John Y H Kim; Liliana C Goumnerova; Peter M Black; Ching Lau; Jeffrey C Allen; David Zagzag; James M Olson; Tom Curran; Cynthia Wetmore; Jaclyn A Biegel; Tomaso Poggio; Shayan Mukherjee; Ryan Rifkin; Andrea Califano; Gustavo Stolovitzky; David N Louis; Jill P Mesirov; Eric S Lander; Todd R Golub
Journal:  Nature       Date:  2002-01-24       Impact factor: 49.962

Review 3.  Medulloblastoma: clinical and biologic aspects.

Authors:  R J Packer; P Cogen; G Vezina; L B Rorke
Journal:  Neuro Oncol       Date:  1999-07       Impact factor: 12.300

4.  Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.

Authors:  Margaret C Thompson; Christine Fuller; Twala L Hogg; James Dalton; David Finkelstein; Ching C Lau; Murali Chintagumpala; Adekunle Adesina; David M Ashley; Stewart J Kellie; Michael D Taylor; Tom Curran; Amar Gajjar; Richard J Gilbertson
Journal:  J Clin Oncol       Date:  2006-03-27       Impact factor: 44.544

5.  Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study.

Authors:  M D Ris; R Packer; J Goldwein; D Jones-Wallace; J M Boyett
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

6.  Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease.

Authors:  T J MacDonald; K M Brown; B LaFleur; K Peterson; C Lawlor; Y Chen; R J Packer; P Cogen; D A Stephan
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

7.  Medulloblastoma: histopathologic and molecular markers of anaplasia and biologic behavior.

Authors:  Hye Sook Min; You Jeong Lee; Kyeongmee Park; Byung-Kyu Cho; Sung-Hye Park
Journal:  Acta Neuropathol       Date:  2006-05-12       Impact factor: 17.088

8.  Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.

Authors:  Halldora K Thorarinsdottir; Brian Rood; Naynesh Kamani; Debbie Lafond; Evelio Perez-Albuerne; Brett Loechelt; Roger J Packer; Tobey J MacDonald
Journal:  Pediatr Blood Cancer       Date:  2007-03       Impact factor: 3.167

9.  Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group.

Authors:  J Russell Geyer; Richard Sposto; Mark Jennings; James M Boyett; Richard A Axtell; David Breiger; Emmett Broxson; Bernadine Donahue; Jonathan L Finlay; Joel W Goldwein; Linda A Heier; Dennis Johnson; Claire Mazewski; Douglas C Miller; Roger Packer; Diane Puccetti; Jerilynn Radcliffe; May Lin Tao; Tania Shiminski-Maher
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

10.  OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas.

Authors:  Talitha de Haas; Esmeralda Oussoren; Wieslawa Grajkowska; Marta Perek-Polnik; Mara Popovic; Lorna Zadravec-Zaletel; Marzia Perera; Giorgio Corte; Oliver Wirths; Peter van Sluis; Torsten Pietsch; Dirk Troost; Frank Baas; Rogier Versteeg; Marcel Kool
Journal:  J Neuropathol Exp Neurol       Date:  2006-02       Impact factor: 3.685

View more
  20 in total

1.  Ultrastructural evidence of ependymal differentiation in a genetically proven atypical teratoid/rhabdoid tumor.

Authors:  Manila Antonelli; Giovanna Cenacchi; Piergiorgio Modena; Isabella Morra; Marco Forni; Felice Giangaspero
Journal:  Childs Nerv Syst       Date:  2009-06-25       Impact factor: 1.475

Review 2.  Pediatric brain tumors: current treatment strategies and future therapeutic approaches.

Authors:  Sabine Mueller; Susan Chang
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

3.  Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas.

Authors:  Wan-Yee Teo; M Tarek Elghetany; Jianhe Shen; Tsz-Kwong Man; Xiaonan Li; Murali Chintagumpala; Jack Meng Fen Su; Robert Dauser; William Whitehead; Adekunle M Adesina; Ching C Lau
Journal:  J Neurooncol       Date:  2014-08-13       Impact factor: 4.130

4.  miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma.

Authors:  Shyamal D Weeraratne; Vladimir Amani; Adrianne Neiss; Natalia Teider; Deborah K Scott; Scott L Pomeroy; Yoon-Jae Cho
Journal:  Neuro Oncol       Date:  2010-12-22       Impact factor: 12.300

Review 5.  Melanotic medulloblastoma in children.

Authors:  Wen-yan Li; Lu Ma; Jian Liu; Hua Yang; Qing Mao
Journal:  Childs Nerv Syst       Date:  2011-01-26       Impact factor: 1.475

6.  LIN28A, a sensitive immunohistochemical marker for Embryonal Tumor with Multilayered Rosettes (ETMR), is also positive in a subset of Atypical Teratoid/Rhabdoid Tumor (AT/RT).

Authors:  Shilpa Rao; R T Rajeswarie; T Chickabasaviah Yasha; Bevinahalli N Nandeesh; Arimappamagan Arivazhagan; Vani Santosh
Journal:  Childs Nerv Syst       Date:  2017-07-25       Impact factor: 1.475

7.  Central nervous system tumors in the first year of life: a clinical and pathologic experience from a single cancer center.

Authors:  Maysa Al-Hussaini; Maisa Swaidan; Usama Al-Jumaily; Awni Musharbash
Journal:  Childs Nerv Syst       Date:  2013-03-24       Impact factor: 1.475

8.  Race, ethnicity, and socioeconomic differences in incidence of pediatric embryonal tumors in the United States.

Authors:  Jennifer M Geris; Logan G Spector
Journal:  Pediatr Blood Cancer       Date:  2020-07-16       Impact factor: 3.167

9.  Mammary analogue secretory carcinoma of the parotid gland as a secondary malignancy in a childhood survivor of atypical teratoid rhabdoid tumor.

Authors:  Jennifer Woo; Raja R Seethala; S Joseph Sirintrapun
Journal:  Head Neck Pathol       Date:  2013-08-07

10.  MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.

Authors:  Livia Garzia; Immacolata Andolfo; Emilio Cusanelli; Natascia Marino; Giuseppe Petrosino; Daniela De Martino; Veronica Esposito; Aldo Galeone; Luigi Navas; Silvia Esposito; Sara Gargiulo; Sarah Fattet; Vittoria Donofrio; Giuseppe Cinalli; Arturo Brunetti; Luigi Del Vecchio; Paul A Northcott; Olivier Delattre; Michael D Taylor; Achille Iolascon; Massimo Zollo
Journal:  PLoS One       Date:  2009-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.